PMID-17581790 – MGF Reduces Loss of Cardiac Function Post-MI
Carpenter V, Matthews K, Devlin G, Stuart S, Jensen J, Conaglen J, Jeanplong F, Goldspink P, Yang SY, Goldspink G, Bass J, McMahon C. Mechano-growth factor reduces loss of cardiac function in acute myocardial infarct. Heart Lung Circ. 2008;17(1):33-39.
Quick Reference
| Property | Value |
|---|---|
| PMID | 17581790 |
| DOI | 10.1016/j.hlc.2007.04.013 |
| Year | 2008 |
| Journal | Heart, Lung and Circulation |
| Study Type | Animal in vivo |
| Evidence Level | V (Oxford CEBM) |
| Sample | Sheep model of acute myocardial infarction |
| Peptide(s) Studied | PEG-MGF |
Key Findings
- MGF (Mechano-Growth Factor) preserved cardiac function following acute myocardial infarction in a sheep model
- MGF-treated animals showed a 35% reduction in compromised (non-functional) myocardial tissue compared to controls
- The cardioprotective mechanism was anti-apoptotic: caspase-3 (a key apoptosis executioner) was absent in MGF-treated cardiac tissue
- This study demonstrated that MGF's biological activity extends beyond skeletal muscle repair to cardiac tissue protection
- The sheep model is clinically relevant due to cardiac anatomy and physiology similarities to humans
- Results suggest MGF may have therapeutic potential in acute cardiac events by limiting infarct expansion through inhibition of cardiomyocyte apoptosis
Study Design
Animal in vivo study using a sheep model of acute myocardial infarction. MI was induced by coronary artery ligation. MGF was administered locally to the infarct zone. Cardiac function was assessed by echocardiography at serial time points. Histological analysis included assessment of infarct size, apoptosis markers (caspase-3 immunohistochemistry), and tissue viability. Treated animals were compared to untreated MI controls.
Limitations
- Small animal numbers inherent to large-animal (sheep) studies
- Local administration to the infarct zone is not practical in clinical settings without surgical access
- Single time-point assessment; long-term cardiac remodeling effects not characterized
- The MGF peptide formulation and dosing protocol may not directly translate to PEG-MGF dosing used in clinical practice
- No comparison to established cardioprotective therapies
- Mechanism of delivery to cardiac tissue in non-surgical settings remains unresolved
Clinical Relevance
This study is significant because it extends MGF's therapeutic potential beyond musculoskeletal repair to cardioprotection. The anti-apoptotic mechanism (caspase-3 suppression) and the 35% reduction in compromised tissue provide compelling preclinical evidence. While direct cardiac application is not the primary use case for PEG-MGF in current peptide protocols, this study supports the broader principle that MGF has tissue-protective effects across multiple organ systems. It also raises the possibility that systemic PEG-MGF administration could have incidental cardioprotective benefits, relevant to practitioners managing patients with cardiovascular risk factors.
Related
#research #animal-in-vivo #evidence-level-V #peg-mgf #recovery #cardiovascular